PMC · DOI:10.1183/13993003.52463-2020·July 7, 2022
“Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension.” Mark Toshner, Colin Church, Lars Harbaum, et al. Eur Respir J 2022; 59: 2002463
Abstract
Linked entities
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsPulmonary Hypertension Research and Treatments
Full text
One of the author names was presented incorrectly in the published version of this article. The author “Sofia S. Villar Moreschi” should have been correctly presented as “Sofia S. Villar”.
The article has been corrected and republished online.